Given emerging evidence that di- and triagonists that include glucagon receptor agonists are effective in treating obesity and dyslipidemia in rodents (73–75), nonhuman primates (76), and humans (77, 78), it is critical to understand the tissue-specific effects of glucagon receptor action. The gene discussed is GCGR; the disease is metabolic syndrome.